{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-23-000025","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.046997+00:00","generated_at":"2026-06-15T05:11:54.938111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q1 revenue $12.1M (-3% YoY); raises FY2023 guidance; FDA updates Safety Communication","bullets":["Total revenue $12.1M (-3% YoY); Advanced Energy $9.7M (-10%); OEM $2.5M (+46%).","Net loss $3.5M ($0.10/share) improved from $5.9M loss in Q1 2022; Adjusted EBITDA loss $4.0M.","Raises FY2023 total revenue guidance to $59-62M (prior $58-61M); Advanced Energy $51-54M; net loss expected ~$10.5M.","FDA updated Safety Communication on May 10 clearing Renuvion APR handpiece for subcutaneous soft tissue coagulation post-liposuction.","Closed sale-leaseback of Clearwater facility for $6.6M net cash; secured $35M credit facility with MidCap."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-23-000025","json":"https://secwatch.observer/filing/0000719135-23-000025.json","markdown":"https://secwatch.observer/filing/0000719135-23-000025.md","text":"https://secwatch.observer/filing/0000719135-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/0000719135-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/apyx-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:11:54.938111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f8da4079c35e8698c6b5f42e212cff9edab119c","claim":"Apyx Medical Corp reported the first quarter ended March 31, 2023 results: revenue $12.1 million, net income Net loss attributable to stockholders of $3.5 million. Guidance raised.","evidence_excerpt":"its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023. First Quarter 2023 Financial Summary : • Total revenue of $12.1 million, down 3% year-over-year. ◦ Advanced Energy revenue of $9.7 million, down 10% year-over-year. ◦ OEM revenue of $2.5 million, up 46% year-over-year. • Net loss attributable to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/0000719135-23-000025-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$12.1 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $3.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}